0001860010-23-000004.txt : 20230609
0001860010-23-000004.hdr.sgml : 20230609
20230609190015
ACCESSION NUMBER: 0001860010-23-000004
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230609
FILED AS OF DATE: 20230609
DATE AS OF CHANGE: 20230609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ORTH ANDREW C.
CENTRAL INDEX KEY: 0001860010
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38210
FILM NUMBER: 231006751
MAIL ADDRESS:
STREET 1: 2100 WHARTON STREET
STREET 2: SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Krystal Biotech, Inc.
CENTRAL INDEX KEY: 0001711279
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 821080209
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2100 WHARTON STREET
STREET 2: SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
BUSINESS PHONE: (412) 586-5830
MAIL ADDRESS:
STREET 1: 2100 WHARTON STREET
STREET 2: SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
4
1
wk-form4_1686351600.xml
FORM 4
X0407
4
2023-06-09
0
0001711279
Krystal Biotech, Inc.
KRYS
0001860010
ORTH ANDREW C.
C/O KRYSTAL BIOTECH, INC.
2100 WHARTON STREET, SUITE 701
PITTSBURGH
PA
15203
0
1
0
0
Chief Commercial Officer
1
Common Stock
2023-06-09
4
M
0
12500
63.55
A
12600
D
Common Stock
2023-06-09
4
S
0
5261
128.1045
D
7339
D
Common Stock
2023-06-09
4
S
0
6906
128.9441
D
433
D
Common Stock
2023-06-09
4
S
0
333
129.6972
D
100
D
Stock Option (Right to Buy)
63.55
2023-06-09
2023-06-09
4
M
0
12500
0
D
2032-02-27
Common Stock
12500
37500
D
The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on March 10, 2023 and will terminate on March 31, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $113.00 per share.
The transaction was executed in multiple trades ranging from $127.5500 to $128.5400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $128.5600 to $129.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $129.5600 to $129.7400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
50,000 options were granted that vest in four equal annual installments beginning on February 28, 2023.
/s/ Andrew Orth
2023-06-09